The growth of the metastatic castrate-resistant prostate cancer market is expected to be driven by the expected rising prevalence of prostate cancer cases due.
Prostate cancer is the most common cancer among men in the U.S. and the second most common cause of cancer-related deaths. African-American men are more likely to get prostate cancer and twice as likely to die from the disease than men of other races. The FDA regulates certain tests and treatments.
Darolutamide receives EU approval for additional indication in prostate cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ORION CORPORATION PRESS RELEASE 1 March 2023 at 13:00 EET Darolutamide receives EU approval for additional indication in prostate cancer European Commission granted approval of